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Abstract 
Blockers selective for different potassium (K ÷) channels were examined for their ability to reverse inhibition of electrically evoked 
contractions of longitudinal muscle-myenteric plexus (lm-mp) by adenosine analogs. Cyclohexyl adenosine (CHA) was selected for these 
studies, since it effectively inhibited contraction (ECs0 33 nM). 4-aminopyridine (4-AP) antagonized the inhibition by the adenosine 
analog, but also stimulated contraction by itself, a- and 3,-dendrotoxin produced the most profound reversal of CHA-induced inhibition, 
while producing a minimal contraction alone. Other blockers produced only nominal reversal of the CHA-induced inhibition. These 
results suggest that inhibition by CHA is mediated via activation of an a- and ~/-dendrotoxin-sensitive K + channel. 
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1. Introduction 
Studies have suggested that regulation of neurotrans- 
mitter elease from nerve endings may involve modulation 
of presynaptic ionic conductances. In particular, modula- 
tion of Ca 2+ or K ÷ conductances [1] may regulate the 
amount of neurotransmitter r leased in response to physio- 
logical stimulation of the nerve. The modulation of these 
conductances may alter the resting membrane potential, 
and therefore the excitability of the nerves, and may alter 
the Ca 2+ influx, which is accepted to be required for 
neurotransmitter r lease. 
Numerous studies have focused on the regulation of 
ACh release by adenosine [2-4]. The mechanism of inhibi- 
tion of ACh release from central neurons by adenosine is 
not clear, but may involve either activation of K + channels 
[5-7] or inhibition of Ca 2+ channels [8]. Fewer studies 
have focused on peripheral cholinergic nerves, which are 
often used as an alternative; cholinergic model. Purinergic 
A 1 receptors have been identified which mediate inhibition 
of ACh release from the hemi-diaphragm [4], from submu- 
cosal neurons [9], and from myenteric plexus neurons 
[10,11]. One report indicates that inhibition of ACh release 
from the lm-mp involves a dihydropyridine-sensitive Ca 2 ÷ 
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channel [12]. The data presented in this latter report cannot 
rule out the possibility that alteration of Ca 2+ channel 
conductance may be secondary to an action on presynaptic 
K ÷ channels. In view of recent results [5,7] indicating that 
purinergic modulation of ACh release from the hippocam- 
pus and the cortex involves activation of a K + channel, the 
objectives of the present study were to determine whether 
K ÷ channels might also mediate purinergic action on the 
myenteric neurons. K ÷ channel blockers which are vari- 
ably selective for inactivating (A-type), non-inactivating 
(delayed rectifier-type), Ca2÷-activated, and ATP-gated 
channels were used in this study. 
2. Materials and methods 
2.1. Tissue preparation 
The lm-mp was prepared as described previously [13]. 
Male Hartley guinea pigs weighing from 400 to 600 g 
were anaesthetized with pentobarbital (50 mg/kg,  i.p.). A 
10 cm segment of the ileum was quickly removed from a 
region approx. 15 cm proximal to the caecum, and put into 
Krebs-Ringer bicarbonate buffer (KRB; composition in 
millimolar: NaC1 117, KC1 4.7, NaH2PO 4 1.2, CaCI 2 2.5, 
MgSO 4 1.2, NaHCO 3 25, and glucose 11; bubbled with 
95% 02-5% CO2). To isolate the lm-mp, the intestine was 
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drawn over a horizontal 1 ml glass pipette. Incisions were 
made gently along the length, one on each side of the 
mesenteric attachment, and the longitudinal muscle with 
the attached myenteric plexus was gently stripped off. In 
some experiments the longitudinal muscle without at- 
tached myenteric plexus was also prepared, as described 
previously [13]. Each strip was suspended in a Sawyer- 
Bartlestone chamber filled with continuously oxygenated 
KRB at 37 ° C. One end of the strip was fixed to the bottom 
of the chamber, and the other end attached to a force 
transducer which was connected to a Coulburn polygraph. 
All data were recorded on a computer interfaced with the 
polygraph, using the Codas software. Each strip was equi- 
librated under 0.7 g of resting tension for 1 h prior to 
initiation of the experiments. 
2.2. Tension studies 
Constant contractions were elicited by maximum elec- 
trical field stimulation (9 V/cm,  0.1 Hz, and 1 ms pulse 
duration). Adenosine analogs and/or K ÷ channel blockers 
were added to the bathing solution following the onset of 
electrical stimulation. None of the solvents used had any 
significant effect on tension development by the lm-mp. 
Results are expressed as the tension developed in the 
presence of the drug(s) as a proportion of the control 
tension (prior to addition of the drug), denoted T/T~. 
Reversal ability (RA) is defined as the ability of a blocker 
to reverse the inhibition of contraction i duced by a certain 
concentration of adenosine analog agonist. The equation 
used to calculate this value was: RA = (R x - lx) / (C - Ix), 
where C is the control tension, Ix is the tension following 
addition of the inhibitor, and R x is the tension following 
addition of the reversing agent (K ÷ channel blocker). An 
RA value of greater than 0.0 indicates the blocker was able 
to reverse the inhibition. 
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Fig. 1. Dose-dependent inhibition of electrically evoked contractions of 
lm-mp by four analogs of adenosine, asdescribed in Section 2. ICs0s for 
inhibition are 23 nM (R(-)N6-phenylisopropyl adenosine, R-PIA), 26 
nM (5'-N-ethylcarboxamido-adenosine, NECA), 33 nM (N6-cyclohexyl 
adenosine, CHA), and 203 nM (2-chloroadenosine, 2-CA). Each point is 
mean + S.E. for 6 determinations. 
lm-mp are very sensitive to inhibition by adenosine recep- 
tor agonists. The results of our comparative study using 
four different adenosine analogs (R(-)N6-phenylisopro - 
pyl adenosine, R-PIA; 5'-N-ethylcarboxamido-adenosine, 
NECA; N6-cyclohexyl adenosine, CHA; 2-chloroadeno- 
sine, 2-CA) are presented in Fig. 1. The rank order of 
potency for inhibition of contraction was R-PIA = NECA 
= CHA > 2-CA. This order is consistent with that which 
would be predicted for A 1 receptor mediated actions of 
adenosine. Further studies were pursued using CHA. 
4-aminopyridine (4-AP) was found to be very effective 
at reversing the inhibition of contraction of the lm-mp by 
CHA (data not shown). However, in the absence of electri- 
cal stimulation or CHA, 4-AP stimulated contraction of the 
lm-mp, the magnitude of which is comparable to the 
2.3. Materials 
a-, /3-, y-, and &dendrotoxin were prepared from 
Dendroaspis angusticeps venom (Latoxan, Rosans, France) 
as described previously [14]. The reduced and carboxy- 
methylated B-chain of fl-bungarotoxin (RCM-B) was pre- 
pared from /3-bungarotoxin (Sigma, St. Louis, MO) as 
described previously [15]. Charybdotoxin, glibenclamide, 
and the adenosine analogs were purchased from Research 
Biologicals (Natick, MA). All other chemicals were reagent 
grade. 
All statistical calculations were made using the 
PCS/Pharm program. 
3. Results 
Similar to results which have been presented elsewhere 
[16], we found that electrically evoked contractions of the 
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Fig. 2. Effect of ~-dendrotoxin on inhibition of electrically evoked 
contractions of lm-mp by 10 nM (O),  30 nM (v ) ,  or 50 nM (v )  CHA. 
ce-dendrotoxin produced minimal contraction in the absence of electrical 
stimulation and CHA ([]).  Each point is the mean + S.E. of 6 determina- 
tions. 
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Table 1 
Reversal ability (RA) of various K + channel blockers at IC50 
Blocker iC50 a Channel blocked b RA ¢ n Reference 
ct-Dendrotoxin 20 nM T 0.75 + 0.11 6 [14] 
/3-Dendrotoxin 10 nM S 0.50 + 0.08 6 [14] 
3,-Dendrotoxin 100 nM S 0.96 + 0.10 9 [14] 
~-Dendrotoxin 100 n M T 0.60 + 0.10 6 [ 14] 
RCM-B 1 nM S 0.31 + 0.02 4 [15] 
Charybdotoxin 10 nM Ca 2 ÷/K  ÷ 0.21 + 0.08 2 [24] 
4-AP 0.1 mM T 1.6 + 0.11 6 [25] 
TEA 0.5 rnM Ca2+/K + 0.28 5:0.05 5 [25] 
Glibenclamide 1 /xM ATP-gated 0.31 + 0.15 4 [26] 
a Values given are approximate IC50 values for nerve ending K ÷ channels (where possible) derived from the reference listed. 
b The type of channel most sensitive to inhibition at the concentration listed, according to the indicated reference. T stands for the fast inactivating S6Rb+ 
efflux thought o be analogous to the A-current channel; S stands for the slowly inactivating S6Rb efflux thought o be analogous to the delayed rectifier 
channel. 
c RA values were calculated as de:;cribed in Section 2, for reversal of approx. 50 % inhibition by CHA (30 nM) of the electrically evoked contractions. 
reversal of inhibition. This suggests that the apparent 
'reversal' may actually be the sum of two different oppos- 
ing actions which may not have a common mechanism of 
action. 4-AP may stimulate the release of excitatory neuro- 
transmitters via action on myenteric neurons, or may have 
a direct action on the smooth muscle. In another experi- 
ment longitudinal muscle without myenteric plexus at- 
tached was used to determine whether 4-AP had direct 
effects on the smooth muscle. 4-AP at concentrations of 30 
and 100 /xM stimulated contractions (calculated as a per- 
cent of the maximal contrac.tion elicited with 30 mM KC1) 
which were about 50% of the contraction stimulated by 
4-AP in the intact lm-mp. Therefore 4-AP can directly 
stimulate the smooth muscle to contract, as well as potenti- 
ate the stimulation of the myenteric plexus neurons. 
Other more selective K + channel blockers were tested 
for their ability to reverse: the CHA-induced inhibition. 
a-dendrotoxin s primarily selective for 'A-type' K ÷ chan- 
nels (similar to 4-AP) at lower concentrations may also 
block the delayed rectifier K ÷ channels. The results pre- 
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Fig. 3. Ability of or-, /3-, "y-. and &dendrotoxin to reverse inhibition of 
electrically evoked contractions of the lm-mp by 30 nM CHA. See text 
for details on calculation of RA. Each point is the mean of 6 to 9 
determinations. S.E. bars have been omitted from the figure for clarity. 
S.E.s of each point are 1-10% of the mean value. 
sented in Fig. 2 show that a-dendrotoxin effectively re- 
versed the CHA-induced inhibition at concentrations simi- 
lar to reported ICs0 values. However, in contrast to 4-AP, 
ct-dendrotoxin had minimal effect on the tension of the 
lm-mp in the absence of electrical stimulation or CHA; it 
produced a very slight contraction at 100 riM, which was 
much smaller than the increase in the electrically evoked 
contraction i the presence of CHA. This indicates that the 
apparent 'reversal' is not the simple addition of two unre- 
lated actions of c~-dendrotoxin and CHA on the lm-mp. 
Three other dendrotoxins were examined for their ability 
to reverse the CHA-induced inhibition, and results are 
summarized in Fig. 3. All four dendrotoxins were able to 
reverse inhibition, c~- and y-dendrotoxin produced the 
greatest reversal over the concentration range examined. 
Several other peptide toxins which have been reported 
to selectively inhibit either the delayed rectifier, or Ca 2+- 
activated K + channels, as well as glibenclamide which is 
reported to inhibit the ATP-gated K + channels were also 
screened for their ability to reverse the CHA induced 
inhibition of contraction. At their reported ICs0's for neu- 
rons, none of these blockers had any effect on the resting 
tension of the lm-mp except for glibenclamide, which 
increased T/T~ by 0.247 0.047. For the electrically evoked 
contractions, the RA results for all blockers are summa- 
rized in Table 1. The RAs for these other K + channel 
blockers were considerably lower, fl-dendrotoxin, &den- 
drotoxin, and RCM-B all had a nominal ability to reverse 
the CHA-induced inhibition. Charybdotoxin and gliben- 
clamide were essentially ineffective, and tetraethyl- 
ammonium chloride (TEA) increased tension only at con- 
centrations greater than the ICs0 for inhibition of nerve 
ending Ca2+-activated K + channels. 
4. Discussion 
Regulation of neurotransmitter r lease has been exten- 
sively examined over the last several years. Currently there 
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are several hypotheses on the mechanism of modulation of 
neurotransmitter r lease, some of which may be interre- 
lated. One hypothesis is that modulation of release in- 
volves alteration in the function of the exocytotic proteins, 
for example by phosphorylation r dephosphorylation [ 17]. 
An alternate hypothesis which has been more extensively 
examined is that alteration in plasma membrane ionic 
currents (e.g., by receptors and/or second messengers) 
will alter the availability of extracellular calcium, which is 
required for the exocytotic release of neurotransmitter [18]. 
The studies described in this report address this second 
hypothesis. 
The actions of adenosine on peripheral ACh release 
have been characterized in the longitudinal muscle- 
myenteric plexus preparations [2,12,19], submucous neu- 
rons [9], and also at motor nerve endings [4,20,21]. Results 
presented here support he previous tudies uggesting that 
inhibition of ACh release from the myenteric plexus is also 
mediated by A 1 receptors (e.g., [22]). The mechanisms 
involved in modulation in this preparation have, however, 
been less well defined. Inhibition of release from myen- 
teric plexus nerve endings has been reported to involve 
inhibition of L-type calcium channels in myenteric plexus 
nerve endings [12], and inhibition of EPSPs in the lm-mp 
preparation. The second messengers which may be in- 
volved in this tissue are not clear, but early studies have 
proposed that a phosphorylation step may be involved [2], 
and the mechanism of inhibition is sensitive to reversal by 
Substance B, a low molecular weight endogenous sub- 
stance [16]. In the central nervous system the second 
messenger system(s) mediating A~ receptor induced inhibi- 
tion of ACh release have also not yet been identified [23]. 
The present report supports the notion that modulation 
of ionic conductances may mediate A 1 receptor induced 
inhibition of contraction of the lm-mp. In particular A 1 
receptor stimulation may activate a K + conductance which 
is sensitive to blockade by both ce- and y-dendrotoxin. 
Reversal of the inhibition by other blockers was not as 
effective at concentrations which have been reported to 
block nerve ending K + channels. Because the apparent 
pharmacological sensitivity of this type K + channel differs 
somewhat from the pharmacological sensitivity of K + 
channels in central nerve endings [14], it is possible that 
the myenteric plexus K + channel has a slightly different 
structure from that in central nerve endings. The concentra- 
tions of drugs used were chosen on the basis of the 
reported K + channel sensitivities for central nerve end- 
ings, and these ICs0 values may not have been appropriate 
for this tissue. However, this issue cannot be resolved until 
the K + channels which populate the myenteric plexus 
nerve endings are more well characterized. 
The results presented here support he notion that modu- 
lation of neurotransmitter r lease by presynaptic receptors 
involves modulation of potassium currents, in addition to 
the factors listed above (phosphorylation, inhibition of 
l-type calcium channels, and Substance B sensitivity). The 
interrelationship between each of these factors to effect 
modulation remains to be elucidated. 
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